KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biomarin Pharmaceutical (BMRN) Shares Outstanding (Diluted Average) (2017 - 2025)

Biomarin Pharmaceutical (BMRN) has disclosed Shares Outstanding (Diluted Average) for 12 consecutive years, with $197.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Shares Outstanding (Diluted Average) changed 0.35% year-over-year to $197.4 million, compared with a TTM value of $197.4 million through Dec 2025, changed 0.35%, and an annual FY2025 reading of $197.4 million, changed 0.35% over the prior year.
  • Shares Outstanding (Diluted Average) was $197.4 million for Q4 2025 at Biomarin Pharmaceutical, up from $192.0 million in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $200.5 million in Q2 2024 and bottomed at $182.6 million in Q3 2021.
  • Average Shares Outstanding (Diluted Average) over 5 years is $192.0 million, with a median of $193.2 million recorded in 2023.
  • The sharpest move saw Shares Outstanding (Diluted Average) fell 6.33% in 2021, then increased 5.71% in 2022.
  • Year by year, Shares Outstanding (Diluted Average) stood at $182.9 million in 2021, then rose by 3.34% to $189.0 million in 2022, then increased by 1.39% to $191.6 million in 2023, then increased by 2.67% to $196.7 million in 2024, then increased by 0.35% to $197.4 million in 2025.
  • Business Quant data shows Shares Outstanding (Diluted Average) for BMRN at $197.4 million in Q4 2025, $192.0 million in Q3 2025, and $196.6 million in Q2 2025.